Ted W. Love, MD, President and CEO of Global Blood Therapeutics (GBT), defended the list price of his company’s recently-approved sickle-cell disease drug Oxbryta
(voxelotor) before an audience of investors in New York . . .
The post Global Blood Therapeutics CEO Defends Price of Sickle-Cell Drug Oxbryta appeared first on GEN – Genetic Engineering and Biotechnology News.
